About Taiho
Our Business
Our Science
December 17, 2015
Taiho and Meiji Enter Into a Co-marketing Agreement in Japan for TAC-202（bilastine）, a Treatment for Allergic Disorders（PDF：554.9 KB）
November 26, 2015
NHI Reimbursement Price Listing and Launch of the Novel Antitumor Agent "Yondelis® IV Infusion"
November 13, 2015
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
September 28, 2015
Novel Antitumor Agent "Yondelis® IV Infusion" Approved in Japan for Treatment of Soft Tissue Sarcoma
September 24, 2015
Taiho Pharmaceutical Announces FDA Approval of LONSURF® (trifluridine and tipiracil) for Refractory Metastatic Colorectal Cancer (mCRC)
September 01, 2015
The First Pre-Meal Drink in the Solmack Series "Solmack 5 Herbal Digestive Support" Nationwide Launch in Japan on Monday, September 7
June 26, 2015
ZOSYN® Receives Approval for the Additional Indication of Febrile Neutropenia
June 15, 2015
Taiho Pharmaceutical Co., Ltd. and Servier Enter Into a License Agreement for Development and Commercialization of an Oral Anticancer Drug TAS-102 in Europe
June 01, 2015
Support for modern people in the prime of life! Designated quasi-drug Tiovita Gold α (Alpha) mini-drink to be launched throughout Japan on June 22
May 14, 2015
Results from Global Phase III Trial of TAS-102 (brand name in Japan: "Lonsurf® ") Published in The New England Journal of Medicine
March 20, 2015
Lonsurf® Combination Tablet for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer Receives Approval in Japan for Partial Change in Indications
March 02, 2015
Taiho Submits TAS-102 (brand name in Japan: "Lonsurf®") Marketing Authorization Application to the European Medicines Agency for the Treatment of Refractory Metastatic Colorectal Cancer
February 23, 2015
Taiho Pharmaceutical Announces TAS-102 (brand name in Japan: "Lonsurf®") New Drug Application for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA
January 05, 2015
Taiho Pharmaceutical Receives Approval to Manufacture and Market ZOSYN® 4.5 for I.V. Infusion Bag, an Injectable Antibiotic Combined with β-Lactamase Inhibitor
